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Abstract
Introduction: Fibroblast-like synoviocytes (FLSs) are a major cell population of the pannus that invades adjacent
cartilage and bone in rheumatoid arthritis (RA). The study was undertaken to determine the effect of interleukin-17
(IL-17) on the survival and/or proliferation of FLSs from RA patients and to investigate whether signal tranducer
and activator of transcription 3 (STAT3) is implicated in this process.
Methods: Bcl-2 and Bax expression in FLSs was determined using the real-time PCR and western blot analysis. The
expression of Bcl-2 and phosphoSTAT3 in synovial tissues was investigated by confocal microscope. Apoptosis of
FLSs was detected by Annexin V/propidium iodide staining and/or phase contrast microscopy. The proliferation of
FLSs was determined by CCK-8 ELISA assay.
Results: The pro-apoptotic Bax is decreased and anti-apoptotic Bcl-2 is increased in FLSs from RA patients
compared with those from patients with osteoarthritis (OA). IL-17 upregulated the expression of Bcl-2 in FLSs from
RA patients, but not in FLSs from OA patients. STAT3 was found to mediate IL-17-induced Bcl-2 upregulation in
FLSs from RA patients. Additionally, IL-17 promoted the survival and proliferation of FLSs from RA patients. Most
importantly, treatment with STAT3 inhibitor reversed the protective effect of IL-17 on FLSs apoptosis induced by
sodium nitroprusside (SNP).
Conclusions: Our data demonstrate that STAT3 is critical in IL-17-induced survival of FLS from RA patients.
Therefore, therapeutic strategies that target the IL-17/STAT3 pathway might be strong candidates for RA treatment
modalities.
Introduction
Rheumatoid arthritis (RA) is a multi-systemic autoimmune
disease of unknown etiology that is characterized by hyper-
plastic synovial membrane capable of destroying adjacent
articular cartilage and bone [1,2]. Synoviocytes, the major
cell population of invasive pannus, actively participate in
the inflammatory processes of RA in the rheumatoid syno-
vium [2]. Synoviocytes produce not only various matrix
metalloproteinase, main effector molecules for digesting
cartilages and bones, but also pro-inflammatory cytokines
such as interleukin (IL)-1 and IL-6 [3], and angiogenic fac-
tors such as VEGF (vascular endothelial growth factor)
[4,5], all of which play major roles in the pathogenesis of
RA [6,7]. In addition, rheumatoid synoviocytes proliferate
abnormally and have characteristics mimicking tumors,
such as a somatic mutation in H-ras [8], p53 [9], and resis-
tance to FAS (TNF receptor superfamily, member 6)-
mediated apoptosis [10].
IL-17 is a highly inflammatory cytokine with robust
effects on stromal cells, resulting in the production of
inflammatory cytokines and recruitment of leukocytes,
and this creates a link between innate and adaptive immu-
nity [11]. IL-17 is produced mainly by pro-inflammatory
T-helper 17 (Th17) cells and both IL-17 and Th17 cells
are deeply implicated with the pathogenesis of RA [7].
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When it comes to the effect of IL-17 on synoviocytes, IL-
17 increases the migration, chemokine gene expression
and invasiveness of synoviocytes. It also inhibits synovio-
cyte apoptosis and enhances metalloproteinase production
leading to cartilage damage [12].
Signal tranducer and activator of transcription 3
(STAT3) is a transcription factor encoded by the STAT3
gene [13]. The STAT3 protein exists in a latent form in
the cytoplasm. STAT3 become phosphorylated on tyro-
sine residues upon receptor activation by cytokines such
as IL-6 and then forms homo- or heterodimers that
translocate to the cell nucleus, where they act as tran-
scription activators. STAT3 plays an essential role in the
differentiation of the Th17 cells [14] and it was reported
that STAT3 is activated in inflamed synovium of an ani-
mal model of RA [15,16].
In the present study, we hypothesized that STAT3,
which is the critical transcription factor for the differentia-
tion of Th17 cells, is implicated in IL-17-dependent survi-
val and proliferation of rheumatoid synoviocytes. We
found that an imbalance between pro-apoptotic Bax and
anti-apoptotic Bcl-2 exists in FLSs from RA patients. In
addition, IL-17 upregulated the expression of Bcl-2 in
FLSs from RA patients. Moreover, we observed that
STAT3 mediated IL-17-induced Bcl-2 upregulation in
FLSs from RA patients. Furthermore, IL-17 promoted the
proliferation of synoviocytes and rescues them from apop-
totic death via the STAT3 pathway. To our knowledge,
our study is the first to demonstrate that STAT3 plays a
critical role in IL-17-induced survival and proliferation of
synoviocytes from RA patients, thus, highlighting the
importance of this pathway in the survival and prolifera-
tion of synoviocytes, a critical cell population in the rheu-
matoid synovium.
Materials and methods
Isolation and culture of FLSs
Synoviocytes were isolated by enzymatic digestion of
synovial tissue specimens obtained from patients with
RA and osteoarthritis (OA) undergoing total joint repla-
cement surgery. The tissue samples were minced into
2- to 3-mm pieces and treated for 4 hours with 4 mg/ml
of type I collagenase (Worthington, Freehold, NJ, USA)
in DMEM at 37°C in 5% CO2. Dissociated cells were then
centrifuged at 500 g, resuspended in DMEM supplemen-
ted with 10% FCS, 2 mM L-glutamine, 100 units/ml of
penicillin, and 100 ng/ml of streptomycin, and plated in
75-cm2 flasks. After overnight culture, nonadherent cells
were removed, and the adherent cells were cultivated in
DMEM supplemented with 10% FCS. The cultures were
kept at 37°C in 5% CO2, and the medium was replaced
every 3 days. The FLSs, from passages three to seven,
were seeded in 24-well plates or 60-mm culture dishes in
10% FCS-supplemented DMEM, and then cultivated for
12 hours at 37°C. Informed consent was obtained from
all the participating subjects. The study received approval
by the Institutional Review Board of Seoul St. Mary’s
hospital.
Real time PCR with SYBR Green
Total mRNA was extracted from the FLSs (1 × 106 cells)
using RNAzol-B, according to the manufacturer’s recom-
mendations (Biotecx, Houston, TX, USA). Reverse tran-
scription of 2 μg total mRNA was carried out at 42°C
using the Superscript Reverse Transcription system
(Takara, Shiga, Japan). PCR amplification of complemen-
tary DNA (aliquot) was performed by adding 2.5 mM
dNTPs, 2.5 units Taq DNA polymerase (Takara), and 0.25
μM sense and antisense primers. The reaction took place
in 25 μl of PCR buffer, consisting of 1.5 mM MgCl2, 50
mM KCl, and 10 mM Tris HCl (pH 8.3). The following
primers were used for each molecule: for Bcl2, 5’-CAG
AAT CCT CTG GAA CTT GAG G-3’(sense) and 5’-
GGT CTC CGA ATG TCT GGA AG-3’(antisense); for
Bax, 5’-GGT GCC TCA GGA TGC G-3’ (sense) and 5’?-
GGA GTC TGT GTC CAC G-?show ’ (antisense): for
IL-17RA, 5’-AGA CAC TCC AGA ACC AAT TCC -3’
(sense) and 5’-TGG TGG AGA GCA ACT CTA AGA-3’
(antisense): for b-actin, 5’-GGA CTT CGA GCA AGA
GAT GG-3’ (sense) and 5’-TGT GTT GGG GTA CAG
GTC TTT G-3’ (antisense). Reactions were processed in a
DNA thermal cycler (PerkinElmer Cetus, Wellesley, MA,
USA) with 30 cycles of 30 seconds of denaturation at 95°
C, and 30 of annealing at 60°C, followed by 30 of elonga-
tion at 72°C. Results are expressed as the ratio of product
to b-actin product.
Western blot
The protein of Bcl-2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), Bax (Santa Cruz Biotechnology), p-
STAT3 (Cell Signaling Technology, Danvers, MA, USA),
STAT3 (Cell Signaling Technology, Danvers, MA, USA)
and b-actin (Sigma, St. Louis, MO, USA) were measured
by Western blot. RA and OA FLSs were incubated with
IL-17 and/or STA21 (Santa Cruz Biotechnology) for 12
hours, a whole cell lysate was prepared from about 2 × 105
cells by homogenization in lysis buffer, and the lysate was
centrifuged at 14,000 rpm for 15 minutes. The protein
concentration in the supernatant was determined using
the Bradford method (Bio-Rad, Hercules, CA, USA). Pro-
tein samples were separated on 10% SDS-PAGE and trans-
ferred to a nitrocellulose membrane (Amersham
Pharmacia, Uppsala, Sweden). The membrane was incu-
bated with 0.1% skim milk in Tris-buffered saline (TBS)
with 0.1% Tween 20 (TTBS). The primary antibodies to
Bcl-2, Bax, p-STAT, STAT3 and b-actin were diluted in
0.1% skin milk/TTBS and incubated for 10 minutes at
room temperature. The membrane was washed three
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times with TTBS, and horseradish peroxidase (HRP)-con-
jugated secondary antibody was incubated for 10 minutes
at room temperature. After washing with TTBS, the hybri-
dized bands were detected using an enhanced chemilumi-
nescence (ECL) detection kit and Hyperfilm-ECL reagents
(Amersham Pharmacia).
Immunohistochemistry
Immunohistochemical staining for Bcl-2 was performed
on FLSs. Briefly, the cells were fixed in 10% formalin
solution at room temperature. The FLSs were depleted of
endogenous peroxidase activity by adding methanolic
H2O2 and were blocked with normal serum for 30 min-
utes. After an overnight incubation at 4 C with polyclonal
anti-Bcl2 (Santa Cruz Biotechnology), the samples were
incubated with biotinylated secondary linking antibodies
for 40 minutes and then incubated with streptavidin-per-
oxidase complex (Vector, Peterborough, UK) for 1 hour
followed by an incubation with 3,3’;-diaminobenzidine
(Dako, Glostrup, Denmark) The samples were counter-
stained with hematoxylin. Samples were photographed
with an Olympus photomicroscope (Tokyo, Japan).
Confocal microscopy
Synovium was snap-frozen in liquid nitrogen and stored
at 80°C. Tissue sections (7 μm) were fixed in 4% parafor-
maldehyde, blocked with 10% goat serum, and stained
with anti-Bcl-2- fluorescein isothiocyanate (FITC) (Santa
Cruz Biotechnology), 4’,6-diamidino-2-phenylindole
(DAPI) (eBioscience, San Diego, CA, USA) and p-STAT3
705-PE (BD Biosciences) or p-STAT3 727-PE (BD Bios-
ciences). Fluorescence images were acquired using an
LSM 510 confocal microscope (Zeiss, Jena, Germany).
Annexin and propidium iodide (PI) stain
FLSs were washed with PBS and then the cells were
stained with Annexin-FITC (BD Biosciences, San Jose,
CA, USA) and PI (BD Biosciences) for 15 minutes at room
temperature. The cells were subjected to flow cytometric
analysis (fluorescence activated cell sorter (FACS) caliber,
BD Biosciences).
Cell proliferation analysis
Cell proliferation was determined by a 2-(2-methoxy-
4-nitrophenyl)-3-(4-nitropenyl)-5-(2, 4-disulfophenyl)-
2H-tetrazolium (CCK-8) kit (Dojindo Laboratories,
Kumamoto, Japan) according to the manufacturer’s
instructions. Briefly, CCK-8 is reduced by dehydro-
genases in cells to yield an orange-colored product (forma-
zan) (Hodgkin et al., 1990 [17]). The amount of formazan
dye generated by the dehydrogenases was directly propor-
tional to the number of living cells. RA FLSs (1 × 104 cells
per well in 0.1% ITSA (insulin-Transferrin Selenium-A)/
DMEM media in a 96-well plate) were cultured in 200 μl
medium in the presence or absence of IL-17 (1 or 10 ng/
ml) for 12 hours. The CCK-8 solution was added to each
well, and the cells were incubated for 2 to 3 hours. Absor-
bance was measured at 450 nm using a microplate reader.
Apoptosis assay
Caspases 3/7 activity was assayed using the Apo-ONE™
Homogeneous Caspase 3/7 assay (Promega, Madison,
WI, USA) according to the manufacturer’s instructions.
Briefly, equal volumes of DMEM and Apo-ONE™ cas-
pase reagent (1:100 profluorescent substrate and lysis
buffer) were added to cells, and the mixture was incu-
bated for 3 hours. Fluorescence (excitation, 499 nm;
emission, 512 nm) was measured using a fluorescence
plate reader. Background fluorescence was determined
by fluorescence from DMEM alone and subtracted from
all experimental values.
Statistical analysis
The experimental values are presented as mean ± SD.
Comparisons of numerical data between the groups
were performed by Student’s t-test or Mann-Whitney
U-test. Values of P < 0.05 were considered statistically
significant.
Results
Bcl-2 overexpression in FLSs from patients with RA
Rheumatoid synoviocytes, the principal components of
pannus, proliferate abnormally in a fashion similar to that
of a tumor, resist apoptosis and also exhibit other features
in common with metastatic cancer cells [2]. Therefore, we
first examined whether there was an imbalance between
pro-apoptotic and anti-apoptotic genes in FLSs from RA
patients compared with FLSs from OA patients. As shown
in Figure 1A, the expression of anti-apoptotic Bcl-2 mRNA
was higher in FLSs from RA patients while the expression
of pro-apoptotic Bax mRNA was lower in FLSs from RA
patients. Western blot analysis also showed similar results
(Figure 1B). Using confocal microscopy, we identified the
expression of Bcl-2 at the single FLS level. As shown in
Figure 1C, Bcl-2 was highly expressed in RA FLSs. These
findings verified that an imbalance between pro-apoptotic
and anti-apoptotic genes exists in FLSs from RA patients.
We also evaluated whether the degree of apoptosis is
different between FLSs in RA and OA. The results
showed that in RA, FLSs were more resistant to SNP-
induced apoptosis compared with FLSs in OA, which was
determined by flow cytometry using PI and Annexin V
(Figure 1D).
IL-17 upregulates the expression of Bcl-2 in FLS from RA
patients
We next investigated the effect of IL-17 on anti-apoptotic
Bcl-2 expression in FLSs from RA patients. The results
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Figure 1 Bcl-2 and Bax expression in synoviocytes in rheumatoid arthritis (RA). (A) Fibroblast-like synoviocytes (FLSs) from RA patients
(n = 3) and osteoarthritis (OA) patients (n = 3) were cultured. The expression of Bcl-2 and Bax mRNA in synoviocytes was evaluated by real-
time PCR. *P < 0.05, **P < 0.01 compared with OA. (B) Expression of Bcl-2 and Bax in synoviocytes was evaluated by western blot. The
representative figure is shown in the left panel. The optical density (OD) ratio of Bcl-2 and Bax between FLSs in RA and OA is shown in the
right panel. *P < 0.05 compared with OA. (C) Expression of Bcl-2 in FLSs in RA and OA was evaluated by confocal microscopy. Bcl-2
expressing FLSs are shown as green. Staining for nuclei by 4’,6-diamidino-2-phenylindole (DAPI) is shown as blue. The representative figure
is shown. (D) Apoptosis was induced by treating the cells with 1 mM sodium nitroprusside (SNP). The degree of apoptosis was assessed
by flow cytometry using propidium iodide (PI) and Annexin V. A (apoptotic cells) were defined as PI-Annexin V+ cells. **P < 0.01
compared with OA.
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showed that treatment with IL-17 increased the expres-
sion of Bcl-2 in FLSs from RA patients both in mRNA
and protein levels (Figure 2A and 2B). However, no sig-
nificant effect of IL-17 on Bax expression was observed
in FLSs from RA patients. Additionally, neither Bcl-2 nor
Bax was changed by treatment with IL-17 in FLSs from
OA patients.
We also investigated the expression of Bcl-2 in RA and
OA FLSs by immunostaining. We found that intense
Bcl-2 staining was observed in FLSs in RA compared
with OA following IL-17 treatment (Figure 2C). We
examined whether IL-17 affects the proliferation of FLSs
from RA patients. The results showed that IL-17 pro-
moted the proliferation of FLSs from RA patients by
CCK-8 kit assay. However, IL-17 did not have a signifi-
cant effect on the FLSs proliferation in OA patients
(Figure 2D). Interestingly, we observed that IL-17RA was
higher FLSs in RA than in OA (Figure 2E).
STAT3 mediates IL-17-dependent Bcl-2 expression in FLSs
from patients with RA
We examined whether IL-17 activates STAT3 in FLSs
from RA patients. We observed that IL-17 treatment
increased phosphorylated STAT3 (p-STAT3 705 and
p-STAT3 727) in FLSs from RA patients, demonstrating
that IL-17 activated STAT3 (Figure 3A). We also found
that treatment with STA21, a STAT3 inhibitor, abrogated
IL-17-induced Bcl-2 expression in FLSs from RA patients
(Figure 3B), demonstrating that STAT3 is involved in
IL-17-induced Bcl-2 expression. When we cultured FLSs
from RA patients with STA21 in the absence of IL-17,
STA21 did not cause significant impact on the expression
of Bcl-2 (data not shown).
To verify this observation ex vivo, immunohistochem-
ical staining for phosphorylated STAT3 (p-STAT3 705
and p-STAT3 727) and Bcl-2 was conducted on the syno-
via of RA and OA patients. As a result, Bcl-2 and phos-
phorylated STAT3 (p-STAT3 727) colocalize in arthritic
joint tissues of RA patients, particularly in the lining
layer of the synovium (Figure 3C).
IL-17 promotes the proliferation of synoviocytes and
rescues the synoviocytes from apoptotic death induced
by SNP via STAT3 pathway
We finally investigated the impact of IL-17 on the survival
and proliferation of FLSs from RA patients. FLSs from RA
patients demonstrated low rate spontaneous apoptosis
(data not shown). SNP (1 mM) induced significant apopto-
sis of FLS, which was determined by calculating PI-negative
Annexin V-positive cells by flow cytometry. As shown in
Figure 4A, IL-17 protects the synoviocytes from apoptotic
death induced by SNP as in a previous report [18].
Figure 4B and Figure 4C show that treatment with IL-
17 dose-dependently rescues the synoviocytes from
SNP-induced apoptotic death. Interestingly, treatment with
a STAT3 inhibitor (STA21) reversed the anti-apoptotic
effect of IL-17 on FLSs, thus verifying that STAT3
mediated IL-17-mediated survival of FLSs from RA
patients (Figure 4D).
Discussion
Human IL-17 was first cloned from a CD4+ T cell library
in 1995 [19] and it is an important pro-inflammatory cyto-
kine. Both Th17 cells, the major producer of IL-17, and IL-
17 play an important role in the pathogenesis of a diverse
group of immune-mediated diseases, including psoriasis
[20,21], multiple sclerosis [22], inflammatory bowel disease
[23] and asthma [24]. Data obtained from humans and
mice demonstrated that IL-17 is critically implicated in the
pathogenesis of RA. A single injection of IL-17 into a nor-
mal mouse knee joint induces inflammatory arthritis [25].
IL-17-knockout mice develop significantly less severe
arthritis than do wild-type mice, and treatment with neu-
tralizing IL-17 antibodies or soluble IL-17 receptor attenu-
ates joint inflammation [26-28]. In humans, IL-17 increases
in the sera and synovial fluid of RA patients and is highly
expressed in the rheumatoid synovium [29,30].
Synoviocytes are the major cell population of inflamed
synovial tissue of RA patients and are found to be a critical
component for the development of RA. With regard to the
effects of IL-17 on synoviocytes, much effort has been
made to identify the impact of IL-17 on synoviocytes.
IL-17 alone induces the production of IL-6 and IL-8 in
FLSs from RA patients [31]. IL-17 can synergize with
other pro-inflammatory cytokines such as TNF-a and
IL-1b and thereby promotes cytokine production in FLSs
from RA patients [32,33]. In addition, IL-17 contributes to
inflammatory cell infiltration into inflamed joint tissues by
inducing the production of chemokines, such as IL-8 and
stromal cell-derived factor-1 (SDF-1) in FLSs from RA
patients [12,34]. It also stimulates the release of degrada-
tive enzymes by synoviocytes, promoting synovium, liga-
ment and cartilage matrix destruction. Moreover, IL-17 is
able to promote the expression of receptor activator of
nuclear factor-B (NF-Kb) ligand (RANKL), the leading
player in osteoclastogenesis, in synoviocytes and osteo-
blasts, which contribute to the bone destruction that is
closed related to functional disability in RA patients [35].
Based on evidence suggesting that IL-17 is critically
involved in the pathogenesis of RA, clinical trials of IL-17-
targeted therapy are underway in patients with RA [36,37].
Until now, only a few reports have investigated the effect
of IL-17 on the survival or proliferation of rheumatoid
synoviocytes [18,38]. Zhang et al. demonstrated that IL-17
promotes the proliferation of FLSs from RA patients and
that Cyr61 is deeply implicated in this event [38]. Toh
et al. reported that IL-17 prolongs the survival of FLSs by
regulating synoviolin expression [18].
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Figure 2 Interleukin (IL)-17 upregulates the expression of Bcl-2 in synoviocytes in rheumatoid arthritis (RA). (A) Fibroblast-like
synoviocytes from patients with RA (RA-FLSs) (n = 3) and fibroblast-like synoviocytes from patients with osteoarthritis (OA-FLSs) (n = 3) were
cultured with IL-17 (0, 1 and 10 ng/ml) for 12 hours. The mRNA expression of Bcl-2 and Bax was evaluated by real-time PCR. The Bcl-2/Bax ratio
is shown in the right panel. *P < 0.05, **P < 0.01 compared with the untreated group. (B) RA-FLSs (n = 3) and OA-FLSs (n = 3) were cultured
with IL-17 (0, 1 and 10 ng/ml) for 12 hours. The expression of Bcl-2 and Bax was measured by western blot. The representative results are shown
in the left panel. The Bcl-2/Bax ratio is shown in the right panel. **P < 0.01 compared with the untreated group. (C) RA-FLSs (n = 3) and OA-FLSs
(n = 3) were cultured with IL-17 (0, 10 ng/ml) for 12 hours. FLSs were stained with anti-Bcl-2 antibody. Stained cells are shown in brown. (D) IL-
17 promoted the proliferation of RA-FLSs, but not that of OA-FLSs. The proliferation of synoviocytes was determined using a CCK-8 kit as
described in Materials and methods. *P < 0.05, **P < 0.01 compared with the untreated group. (E) The expression of IL-17RA mRNA in OA and
RA FLSs was evaluated by real-time PCR. *P < 0.05 compared with OA.
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Figure 3 Signal tranducer and activator of transcription 3 (STAT3) mediates IL-17-induced Bcl-2 upregulation in synoviocytes in
rheumatoid arthritis (RA). (A) IL-17 upregulated the expression of STAT3 in RA-fibroblast-like synoviocytes (FLSs). RA-FLSs (n = 3) were cultured
with IL-17 (0, 1 and 10 ng/ml) for 12 hours. The expressions of STAT3 and phosphorylated STAT3 (pSTAT3 705 and pSTAT3 727) were measured
by western blot. The representative figure is shown in the left panel. Data are expressed as mean ± SD of three independent experiments.
*P < 0.05, **P < 0.01 compared with the untreated group. (B) RA-FLSs (n = 3) were cultured with IL-17 (0 and 10 ng/ml) in the presence or
absence of STAT3 inhibitor (STA21 50 μM) for 12 hours. The expression of Bcl-2 mRNA and protein was evaluated by real-time PCR and western
blot. (C) Co-localization of STAT3 and Bcl-2 in rheumatoid synovium. Tissue sections from the synovium of patients with RA (n = 3) or
osteoarthritis (OA) (n = 3) were stained with anti-Bcl-2, anti- pSTAT3 727 and anti-pSTAT3 705 antibodies. Co-localization of STAT3 and Bcl-2 was
observed in synovial lining cells of RA patients. The representative figure is shown.
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Figure 4 IL-17 promotes the proliferation of synoviocytes and rescues the synoviocytes from apoptotic death induced by sodium
nitroprusside (SNP) via the STAT3 pathway. (A) IL-17 protects synoviocytes from apoptotic death. RA- fibroblast-like synoviocytes (FLSs) (n =
3) were cultured with IL-17 (0, 1 and 10 ng/ml) in the presence or absence of 1 mM SNP in serum-free DMEM for 24 hours. The degree of
apoptosis was assessed by flow cytometry using propidium iodide (PI) and Annexin V. Representative results are shown. (B) Phase contrast
microscopy showed that treatment with IL-17 dose-dependently rescued synoviocytes from apoptotic death induced by SNP. The percentage of
cell area was determined using the TOMORO analySIS TS Lite Image program (Olympus, Münster, Germany). Data are expressed as mean ± SD.
*P < 0.05, **P < 0.01 compared with untreated group. (C) Apoptosis activity was assayed using a caspase 3/7 assay kit and a fluorescence
luminometer. Data are expressed as mean ± SD. **P < 0.01 compared with the SNP-treated group. (D) Apoptosis activity was indicated by
fluorescence using a caspase3/7 assay kit. The results of three individual experiments are shown.
Lee et al. Arthritis Research & Therapy 2013, 15:R31
http://arthritis-research.com/content/15/1/R31
Page 8 of 10
STAT3 is an essential transcription factor in cellular phy-
siology. It is activated through phosphorylation of tyrosine
705 and serine 727 in response to various cytokines and
growth factors including interferons, epidermal growth fac-
tor, IL-5, IL-6, IL-21, hepatic growth factor, leukemia inhi-
bitor factor, and bone morphogenic protein 2, and also the
hormone leptin. STAT3 mediates the expression of a vari-
ety of genes in response to cell stimuli, thus, playing a key
role in many cellular processes such as cell growth and
apoptosis. One report has shown that survival of rheuma-
toid synoviocytes is dependent on STAT3 [39]. It is well-
known that STAT3 is critical in the differentiation of Th17
cells, the major IL-17 producing cells [14]. In contrast, only
one report has indicated that STAT3 is downstream of IL-
17 signaling in human airway smooth muscle cells [40].
Our results demonstrated for the first time that STAT3 is
critical in IL-17 signaling in patients with RA. Thus, a strat-
egy targeting STAT3, which is critical both in the differen-
tiation of IL-17-producing Th17 cells and IL-17 signaling,
might be a good therapeutic tool to treat patients with RA.
In the current study, we used STA21 as a STAT3
inhibitor. STA-21 is a small molecule with potent
STAT3-inhibiting activity. It impedes STAT3 DNA
binding activity, STAT3 dimerization and STAT3-
dependent luciferase activity. It also inhibits breast can-
cer cells that express constitutive active STAT3 [41].
In this study, IL-17 increased Bcl-2 expression and pro-
moted the proliferation FLSs in RA patients, but not in
OA patients (Figure 2A, B and 2D). Therefore, it is concei-
vable that FLSs from RA patients are more responsive to
IL-17 stimulation than those from OA patients. These
findings might be partially explained by the differential
expression of the IL-17 receptor between FLSs from RA
patients and FLSs from OA patients [42]. Our results also
showed that the expression of IL-17 receptor (IL-17RA)
was higher in FLSs from RA patients than in those from
OA patients (Figure 2E).
In the present study, we found that pro-apoptotic Bax
gene is decreased and anti-apoptotic Bcl-2 gene increased
in FLSs from RA patients compared with those from OA
patients. IL-17 upregulated the expression of Bcl-2 in FLSs
from RA patients, but not in FLSs from OA patients.
Additionally, STAT3 mediated IL-17-induced Bcl-2 upre-
gulation in FLSs from RA patients. Moreover, we observed
that IL-17 promoted the proliferation of synoviocytes and
rescued the synoviocytes from apoptotic death via the
STAT3 pathway. Taken together, these findings suggest
that the IL-17/STAT3 pathway is essential for the survival
and proliferation of synoviocytes.
Conclusions
In conclusion, the present study demonstrated that
STAT3 is critical in IL-17-mediated survival of FLSs in
patients with RA. Our data underline the importance of
the IL-17/STAT3 pathway as a strong potential candi-
date for therapeutic modulation of RA.
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